MRNA

Moderna

D
MRNA
USD
-1.49
(-2.8776%)
Market Closed
722,935.00
Volume
-9.925
EPS
-
Div Yield
-3.256678
P/E
19,331,276,348.70
Market Cap
Today
-2.8776%
1 Week
-7.470%
1 Month
-14.342%
6 Months
-58.452%
12 Months
-31.745%
Year To Date
-49.452%
All Time
232.386%
Signals
avatar
Abdilatif
9 months ago
sell
MRNA
MRNA@101.020
01.02.2024 09:45
Profit
357.00
TP1: 80.000
SL: 105.723
Close Price
97.450
Closed At
2024-02-05 09:51
avatar
Abdilatif
9 months ago
sell
MRNA
MRNA@101.830
29.01.2024 10:09
Profit
-175.00
TP1: 101.829
TP2: 84.000
SL: 104.928
Close Price
105.330
Closed At
2024-01-29 18:15
More
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
B
BNTX
0.99
(0.9269%)
USD
N
NVAX
0.23
(2.5713%)
USD
PFE
PFE
0.105
(0.3839%)
USD
AZN
AZN
0.335
(0.5207%)
USD
JNJ
JNJ
-1.03
(-0.6528%)
USD
MRK
MRK
0.46
(0.4567%)
USD
GSK
GSK
0.76
(2.117%)
USD
BMY
BMY
-0.57
(-1.0313%)
USD
REGN
REGN
8.505
(1.0417%)
USD
ABBV
ABBV
-0.78
(-0.3876%)
USD

Title:
Moderna

Sector:
Healthcare
Industry:
Biotechnology
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Do you need help or have a question?
Contact Us